Secondary Logo

Journal Logo

Articles by Margaret A. Fischl

Brief Report: PrEP Eligibility Among At-Risk Women in the Southern United States: Associated Factors, Awareness, and Acceptability

Patel, Anar S.; Goparaju, Lakshmi; Sales, Jessica M.; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 80(5):527-532, April 15, 2019.

Use of Nonantiretroviral Medications That May Impact Neurocognition: Patterns and Predictors in a Large, Long-Term HIV Cohort Study

Radtke, Kendra K.; Bacchetti, Peter; Anastos, Kathryn; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 78(2):202-208, June 1, 2018.

Open-Label Study of a Twice-Daily Indinavir 800-mg/Ritonavir 100-mg Regimen in Protease Inhibitor-Naive HIV-Infected Adults

Young, Benjamin; Fischl, Margaret A.; Wilson, Helene M.; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 31(5):478-482, December 15th, 2002.

A Randomized, Controlled, Double-Blind Study Comparing the Survival Benefit of Four Different Reverse Transcriptase Inhibitor Therapies (Three-Drug, Two-Drug, and Alternating Drug) for the Treatment of Advanced AIDS

Henry, Keith; Erice, Alejo; Tierney, Camlin; More

Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 19(4):339-349, December 1st, 1998.

Phase I Study of Atevirdine Mesylate (U-87201E) Monotherapy in HIV-1-Infected Patients

Demeter, Lisa M.; Meehan, Patricia M.; Morse, Gene; More

Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 19(2):135-144, October 1st, 1998.

Safety and Antiviral Activity of Combination Therapy With Zidovudine, Zalcitabine, and Two Doses of Interferon-α2a in Patients With HIV: AIDS Clinical Trials Group Study 197

Fischl, Margaret A.; Richman, Douglas D.; Saag, Michael; More

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 16(4):247-253, December 1st, 1997.

Phase I/II Study of the Toxicity, Pharmacokinetics, and Activity of the HIV Protease Inhibitor SC-52151

Fischl, Margaret A.; Richman, Douglas D.; Flexner, Charles; More

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 15(1):28-34, May 1st, 1997.

Combination Therapy with Recombinant Human Soluble CD4-Immunoglobulin G and Zidovudine in Patients with HIV Infection: A Phase I Study

Meng, Tze-Chiang; Fischl, Margaret A.; Cheeseman, Sarah H.; More

Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 8(2):152-160, February 1995.

Prevalence and Patterns of Use of Concomitant Medications Among Participants in Three Multicenter Human Immunodeficiency Virus Type I Clinical Trials

Fogelman, Ilana; Lim, Lynette; Bassett, Roland; More

Journal of Acquired Immune Deficiency Syndromes. 7(10):1057-1063, October 1994.

The Safety and Efficacy of Combination N-Butyl-Deoxynojirimycin (SC-48334) and Zidovudine in Patients with HIV-1 Infection and 200–500 CD4 Cells/mm

Fischl, Margaret A.; Resniek, Lionel; Coombs, Robert; More

Journal of Acquired Immune Deficiency Syndromes. 7(2):139-147, February 1994.

Weekly Doxorubicin in the Treatment of Patients with AIDS-Related Kaposi's Sarcoma

Fischl, Margaret A.; Krown, Susan E.; O'Boyle, Kevin P.; More

Journal of Acquired Immune Deficiency Syndromes. 6(3):259-264, March 1993.

The Effect of Zidovudine Treatment on Serum Neopterin and β2-Microglobulin Levels in Mildly Symptomatic, HIV Type 1 Seropositive Individuals

Bass, Hong Z.; Hardy, W. David; Mitsuyasu, Ronald T.; More

Journal of Acquired Immune Deficiency Syndromes. 5(3):215-221, March 1992.

A Phase I Study of Recombinant Human Interferon-α2a or Human Lymphoblastoid Interferon-αn1 and Concomitant Zidovudine in Patients with AIDS-Related Kaposi's Sarcoma

Fischl, Margaret A.; Uttamchandani, Raj B.; Resnick, Lionel; More

Journal of Acquired Immune Deficiency Syndromes. 4(1):1-10, January 1991.